Exact Sciences Corporation Aktie News

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests today announced the publication of “Comparing Benefit-to-Burden Ratios of Endorsed and Emerging Colorectal Cancer Screening Strategies” in the Journal of the National Cancer Institute.1 The modeling study found that Cologuard Plus™, a triennial next-generation multita...

Exact Sciences earns a BUY rating, driven by innovation in non-invasive cancer detection and the recent launch of Cancerguard. EXAS's core products—Cologuard, Oncotype DX, and OncoDetect—deliver strong revenue growth, while Cancerguard expands its addressable market into multi-cancer early detection. Risks include regulatory hurdles, payer coverage, and competition from Guardant and Grail, but ...

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, is teaming up with actor and horror icon Matthew Lillard to encourage people 45 and older to get screened for colorectal cancer—the nation's second leading cause of cancer-related death.1 Best known for his roles in cult classics like Scream and Scooby-Doo, Lillard i...

DALLAS--(BUSINESS WIRE)--Healthmine and Exact Sciences partner to increase colorectal cancer screening rates through at-home testing and health plan incentives.

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leader in cancer diagnostics, today announced the launch of the Cancerguard™ test, a new multi-cancer early detection (MCED) blood test that is now available as a laboratory-developed test (LDT) in the United States. Cancerguard is the first MCED test commercially available that analyzes multiple biomarker classes to help de...

Exact Sciences Corporation (NASDAQ:EXAS ) Baird 2025 Global Healthcare Conference September 9, 2025 10:50 AM EDT Company Participants Kevin Conroy - Chairman of The Board & CEO Aaron Bloomer - Chief Financial Officer Raj Pudipeddi - EVP, Chief Growth Officer Conference Call Participants Catherine Ramsey - Robert W. Baird & Co. Incorporated, Research Division Presentation Catherine Ramsey Senior...

Exact Sciences Corporation (NASDAQ:EXAS ) Wells Fargo 20th Annual Healthcare Conference 2025 September 3, 2025 1:30 PM EDT Company Participants Aaron Bloomer - Chief Financial Officer Conference Call Participants Brandon Couillard - Wells Fargo Securities, LLC, Research Division Presentation Brandon Couillard MD & Equity Analyst All right. Good afternoon.

ST. LOUIS--(BUSINESS WIRE)--Geneoscopy announced that Exact Sciences has withdrawn its motion for a preliminary injunction regarding the '781 patent and the ‘746 patent.